Success Metrics

Completion Rate
0%(0/2)
Active Trials
0(0%)
Terminated
2(100%)

Phase Distribution

Ph phase_1
2
100%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
2(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Terminated(2)

Detailed Status

Terminated2

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
0.0%
Most Advanced
Phase 1

Trials by Phase

Phase 12 (100.0%)

Trials by Status

terminated2100%

Recent Activity

0 active trials
Showing 2 of 2
terminatedphase_1

Study With Lu AF20513 in Patients With Mild Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI) Due to AD

NCT03819699
terminatedphase_1

A Study to Evaluate the Long-term Safety and Tolerability of Lu AF20513 and the Antibody Response in Patients With Alzheimer's Disease (AD)

NCT03668405

Clinical Trials (2)

Showing 2 of 2 trials
NCT03819699Phase 1

Study With Lu AF20513 in Patients With Mild Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI) Due to AD

Terminated
NCT03668405Phase 1

A Study to Evaluate the Long-term Safety and Tolerability of Lu AF20513 and the Antibody Response in Patients With Alzheimer's Disease (AD)

Terminated

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2